Journal Scans
Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study
Maintenance With Simplified LV5FU2 vs Chemotherapy Discontinuation in Unresectable Metastatic Colorectal Cancer
B Chibaudel, F Maindrault-Goebel, G Lledo, L Mineur, T André, M Bennamoun, M Mabro, P Artru, E Carola, M Flesch, O Dupuis, P Colin, AK Larsen, P Afchain, C Tournigand, C Louvet, A de Gramont
Yes
20090828
2009 Sept 28
J Clin Oncol
Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study
J Clin Oncol. 2009 Sept 28;[Epub Ahead of Print], B Chibaudel, F Maindrault-Goebel, G Lledo, L Mineur, T André, M Bennamoun, M Mabro, P Artru, E Carola, M Flesch, O Dupuis, P Colin, AK Larsen, P Afchain, C Tournigand, C Louvet, A de Gramont
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
SUMMARY
OncologySTAT Editorial Team
Half of all patients with colorectal cancer will develop metastasis. Chemotherapy regimens including oxaliplatin, leucovorin (LV), and 5-fluorouracil (FU) (ie, FOLFOX) are among those used to improve survival and quality of life in these patients. However, oxaliplatin is associated with severe peripheral sensory neuropathy. The feasibility of discontinuing oxaliplatin and instituting maintenance therapy has been investigated in the Optimized Leucovorin [LV]-Fluorouracil [FU]-Oxaliplatin (OPTIMOX)-1...
